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BACKGROUND: The objective of this investigation was to establish independent predictors of follicle-stimulating
hormone (FSH) threshold dose in anovulatory women undergoing ovulation induction with FSH preparations.
METHODS: One hundred and ﬁfty-one patients with WHO Group II anovulatory infertility failing to ovulate or con-
ceive on clomiphene citrate underwent ovarian stimulation with FSH-only preparations following a low-dose step-up
protocol. The individual FSH threshold dose was deﬁned as the FSH dose when meeting the human chorionic gonado-
trophin criteria (one follicle  17 mm, or 2–3 follicles  15 mm). The inﬂuence of demographics, physical character-
istics, obstetric and infertility and menstrual cycle history, ovarian ultrasonography, endocrine parameters and type
of gonadotrophin preparation on the FSH threshold dose was assessed through multiple regression analysis.
RESULTS: In the univariate analysis, age, body mass index (BMI), failure to ovulate with clomiphene citrate,
menstrual cycle history (amenorrhea, oligomenorrhea or anovulatory cycles of 21–35 days), mean ovarian volume,
LH/FSH ratio, testosterone and free androgen index were signiﬁcant (P<0.05) predictors of FSH threshold dose.
In the multivariate analysis, menstrual cycle history, mean ovarian volume and BMI remained signiﬁcant (P<0.001).
CONCLUSIONS: The individual FSH threshold dose for ovulation induction in anovulatory women can be predicted
based on three variables easily determined in clinical practice: menstrual cycle history, mean ovarian volume and
BMI. A FSH dosage nomogram was constructed based on these parameters.
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Introduction
Approximately 20–30% of the women seeking fertility treat-
ment present with anovulation (Healy et al., 1994). Clomi-
phene citrate has been used as the ﬁrst line treatment for
inducing ovulation in anovulatory women. In most women
who failed to ovulate or conceive with clomiphene citrate,
ovarian stimulation with gonadotrophins leads to ovulation
(Coelingh-Benning et al., 1998; Yarali et al., 1999; Platteau
et al., 2006; Balen et al., 2007). The use of low-dose step-up
protocols has been shown to be successful in producing mono-
follicular development in more than half of the women
undergoing stimulation with gonadotrophins, and thereby
minimizing the risk of multiple follicular development and
the associated risks of ovarian hyperstimulation syndrome
(OHSS) and multiple pregnancy (Homburg and Howles, 1999).
A typical low-dose step-up protocol starts with 50–75 IU/
day of follicle-stimulating hormone (FSH) or menotrophins
for 7 to 14 days, and the dose is then increased by 37.5–
50 IU/day if adequate response is not obtained. For some
patients, the dose of gonadotrophin needed to provide adequate
response is relatively high and the use of low-dose regimens
will in these cases lead to stimulations of long duration. A
long ovarian stimulation is associated with more monitoring
visits and would be expected to result in increased costs and
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Advance Access publication on March 26, 2008inconvenience for the patients. Selection of the most optimal
starting dose of gonadotrophin for each individual patient
should minimize these disadvantages, while ensuring adequate
response.
Imani et al. (1998) have identiﬁed clinical and laboratory
parameters such as body mass index (BMI), menstrual cycle
history, mean ovarian volume and free androgen index (FAI)
which can predict ovulation in WHO type II anovulatory
women undergoing clomiphene citrate treatment. A similar
investigation in anovulatory women undergoing ovulation
induction with gonadotrophins suggested BMI, clomiphene
citrate resistance, serum insulin-like growth factor-1 (IGF-1)
and serum FSH as signiﬁcant predictors of FSH threshold
dose (Imani et al., 2002). The clinical application of this
latter result is complicated by the fact that the IGF-1 assay is
not part of most clinics standard battery for laboratory screen-
ing of anovulatory patients. Therefore, further data are needed
to identify simple parameters which can predict the FSH
threshold dose in women who will undergo low-dose protocols
with gonadotrophins.
The purpose of the present prospective investigation was to
evaluate the inﬂuence on the FSH threshold dose of clinical,
sonographic and endocrine parameters available at the start
of ovarian stimulation as well as type of FSH preparation to
be used in a low-dose step-up protocol. The data from this
investigation form the basis for constructing a nomogram
which provides an indication of the expected FSH threshold
dose for the individual patient, facilitating the selection of
the most appropriate starting FSH dose for ovarian stimulation.
Materials and Methods
Study population and design
This investigation included 151 women with anovulatory WHO Group
II infertility who were included in a randomized, open label, assessor-
blind, parallel group, multicentre, multinational, non-inferiority study
comparing two different FSH preparations (highly puriﬁed (HP)-FSH,
BRAVELLE, Ferring Pharmaceuticals A/S, Copenhagen, Denmark
and recombinant FSH (rFSH), follitropin alfa, GONAL-F, Serono,
Geneva, Switzerland) with respect to ovulation rate. Patients were
recruited in 22 fertility centres (12 in Belgium, 7 in Denmark and 3
in the UK) that on average each included seven patients, ranging
from 2 to 20. A detailed description of the study population, all
inclusion and exclusion criteria, all study procedures, as well as the
main outcome of the study, is described in detail in a separate publi-
cation (Balen et al., 2007).
Patients were to be 18–39 years of age with BMI 19–35 kg/m
2,
have been diagnosed with infertility for  1 year, have chronic anovula-
tion (amenorrhea, oligomenorrhea or anovulatory cycles based on pro-
gesterone levels in patients with cycle lengths of 21–35 days) and have
failed to ovulate with clomiphene citrate doses of at least 100 mg/day
for at least 5 days or failed to conceive after three cycles of ovulation
inductionwithclomiphenecitrate.Womenwithahistoryof  12 unsuc-
cessful ovulation induction cycles, persistent ovarian cysts ( 15 mm)
for .1 cycle or ovarian endometrioma on ultrasound and any signiﬁ-
cant systemic disease, endocrine or metabolic abnormalities were
excluded. The study was carried out in accordance with the declaration
of Helsinki on good clinical practice and ethical committee approval
was obtained in all participating centres.
All patients underwent screening assessments prior to start of
ovarian stimulation. These included evaluation of demographics
(age), physical characteristics (body weight, height, waist and hip
circumference), obstetric history (previous pregnancies, previous
live births), infertility history (duration of infertility, number of pre-
vious ovulation induction cycles with clomiphene citrate and in
total, failure to ovulate with clomiphene citrate, failure to conceive
with clomiphene citrate) and menstrual cycle history. Just prior to
the ﬁrst dose of gonadotrophin, patients underwent a transvaginal
ultrasound and blood sampling for endocrine evaluation. The sono-
graphic recordings comprised dimensions of right and left ovary,
number of follicles (antral follicles .2 mm) in right and left ovary
and endometrial thickness. The endocrine evaluation included the fol-
lowing parameters: luteinizing hormone (LH), FSH, estradiol (E2),
prolactin, total testosterone, sex hormone binding globulin (SHBG),
FAI, glucose and insulin. Chemiluminescent immunometric assays
were used for LH, FSH, prolactin, total testosterone and SHBG, and
radioimmunoassays were used for E2 and androstenedione, whereas
a hexokinase assay was used for glucose and immulite technology
was applied for analysis of insulin. All endocrine analyses were con-
ducted by a central laboratory (Quest Diagnostics—Quest Diagnostics
Limited, Heston, UK; Quest Diagnostics Limited, Van Nuys, CA,
USA; Nichols Institute, San Juan Capistrano, CA, USA). FAI was cal-
culated as (total testosterone/SHBG)   100.
All patients underwent ovarian stimulation following a low-dose
step-up protocol. Stimulation was started 2–5 days after a spon-
taneous or progesterone-induced menstrual bleed. The starting dose
of gonadotrophin was 75 IU daily, which was maintained for 7 days.
After the ﬁrst 7 days, the gonadotrophin dose was either maintained
or increased by 37.5 IU increments according to individual response.
Patients were maintained on any speciﬁc dose level for at least 7 days.
The maximum allowed daily dose was 225 IU and patients were
treated withgonadotrophinfor a maximum of 6 weeks. Gonadotrophin
stimulation was maintained until at least one of the following criteria
for human chorionic gonadotrophin (hCG) administration was met:
one follicle with a diameter of 17 mm or greater, or 2–3 follicles
with a diameter of 15 mm or greater. Patients were not given hCG
in either of the following situations: no follicular response after 6
weeks of gonadotrophin treatment,  4 follicles with diameters of
 15 mm or serum E2 levels .2000 pg/ml. Patients who reached
the hCG criteria received a single s.c. or i.m. injection of hCG
(PROFASI, Serono) at a dose of 5000 IU to trigger ovulation. At
least one blood sample was taken during the midluteal phase (6–9
days after hCG administration) and analysed for progesterone by a
central laboratory using competitive immunoassay using direct chemi-
luminometric technology with a sensitivity of 0.48 nmol/l (Quest
Diagnostics Limited, UK). Ovulation was deﬁned as a mid-luteal
serum progesterone concentration of  25 nmol/l(  7.9 ng/ml).
The FSH threshold dose was deﬁned as the dose of FSH that was
given when the criteria for hCG was reached. The analysis involved
the inﬂuence of the type of gonadotrophin preparation (i.e. HP-FSH
or rFSH) as well as of clinical, sonographic and basal endocrine
parameters on the FSH threshold dose. All potential predictive
variables were investigated: age, BMI, waist–hip ratio, previous
pregnancy, duration of infertility, failure to ovulate on clomiphene
citrate, menstrual cycle history (amenorrhea if the patient had absent
menstruation, oligomenorrhea if menstruation intervals were longer
than 35 days or cycle length of 21–35 days in which case anovula-
tion had been documented by progesterone levels), total number of
follicles, mean ovarian volume (based on length, width and depth
of both right and left ovary), LH/FSH ratio, androstenedione, total
testosterone, SHBG, FAI, prolactin, estradiol, glucose, insulin and
insulin/glucose ratio.
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The primary end-point of the study was ovulation rate after one cycle
of gonadotrophin treatment, and these data have been reported else-
where (Balen et al., 2007). The inﬂuence of the selected clinical, sono-
graphic and endocrine parameters as well as type of gonadotrophin on
FSH threshold dose were assessed in univariate and multivariate ana-
lyses using proportional odds polytomous logistic regression models
(an extension of the model and method for binary response). Multi-
variate analyses were performed including characteristics that had
statistically signiﬁcant inﬂuence on the FSH threshold dose in the
univariate analysis ﬁrst by entering all selected characteristics into
the polytomous logistic model in a forward selection approach and
secondly by entering all selected characteristics into the polytomous
logistic model using a backward elimination approach. P-values of
,0.05 were regarded as statistically signiﬁcant. Score tests were used
to evaluate the proportional odds assumption and Wald tests were
used to assess the inﬂuence of the baseline characteristics on the FSH
threshold dose. For the present analysis, all parameters were analysed
as continuous variables, except for type of gonadotrophin, previous
pregnancy, failure to ovulate on clomiphene citrate and menstrual
cycle history (glucose and insulin were categorical variables as
normal/abnormal and insulin/glucose ratio was a continuous variable).
In addition to the above, the model was evaluated on the subset of
patients with mono-follicular development (one follicle  17 mm and
no follicles of 15–16 mm). In this evaluation, the same set of variables
was used as selected for the main model according to the above pro-
cedure. The predictive performance of the model was assessed by
using the ‘leave-one-out’ cross-validation procedure. In addition, the
residual standard error after a standard multiple regression analysis
was evaluated.
Finally, ROC curves were produced and AUC under the ROC
curves were calculated. For the standard situation where ROC
curves are used, the classiﬁcation is binary, whereas the threshold
dose had four possible outcomes (87.5, 112.5, 150 and 187.5) and
the prediction model therefore also predicts into four classes. A con-
sensus approach on how to handle multiclass ROC has not been
reached (Landgrebe and Duin, 2007), but when the outcome classes
are ranked, ROC curves can be made for each of the possible levels
(Waegeman et al., 2006).
Results
The clinical, sonographic and endocrine characteristics of the
151 patients included in the study are shown in Table I. The
mean age of the study population was 28.9 years, ranging
from 19 to 39 years. The BMI spanned from 18 to 39 kg/m
2,
with 54% of the patients having a normal BMI, 32% being
overweight and 14% being obese and with the mean BMI
being 24.8 kg/m
2. On average, patients had been infertile for
3 years and had undergone four previous ovulation induction
cycles with clomiphene citrate, with 34% of the patients failing
to ovulate on clomiphene citrate. Regarding menstrual cycle
history, 56% of the patients were oligomenorrheic and 15%
amenorrheic. An LH/FSH ratio above 1 was noted for 59%
of the patients. Among the 151 patients who started stimulation
with FSH (HP-FSH 73, rFSH 78), 132 patients met the hCG
criteria (HP-FSH 65, rFSH 67) and contributed with data to
the analysis of FSH threshold dose. There were 19 patients
who initiated gonadotrophin therapy but did not contribute to
this analysis; 10 discontinued from the study during ovarian
stimulation (ﬁve because of excessive response), 2 had
spontaneous ovulation and 7 received hCG despite either not
meeting or exceeding the hCG criteria.
Table II provides the outcome of the univariate and multi-
variate analysis for the predictors of FSH threshold dose.
Eight parameters were statistically signiﬁcant predictors of
FSH threshold dose (P , 0.05): age, BMI, failure to ovulate
with clomiphene citrate, menstrual cycle history (amenorrhea,
oligomenorrhea or anovulatory cycles with cycle length 21–35
days), mean ovarian volume, LH/FSH ratio, testosterone and
FAI. The type of gonadotrophin preparation, HP-FSH or
rFSH, did not predict FSH threshold dose. All eight signiﬁcant
parameters were included in a multivariate analysis which
showed that only three of the parameters were independently
statistically signiﬁcant (P-values , 0.001) predictors of FSH
threshold dose: BMI, mean ovarian volume and menstrual
cycle history (Table III). The odds for needing .75 IU FSH
were 1.18 [95% conﬁdence interval (CI): 1.07–1.29] for
BMI and 1.22 [95% CI: 1.09–1.37] for mean ovarian
volume; thus the higher the BMI and ovarian volume prior to
start of stimulation, the higher the FSH threshold dose. Regard-
ing the menstrual cycle history, the odds for needing a FSH
Table I. Clinical, sonographic and endocrine parameters just prior to starting
ovarian stimulation with FSH (Day 1 of stimulation).
Total
(n ¼ 151)
Clinical parameters
Age (years) 28.9+3.7
Body weight (kg) 68.6+13.2
BMI (kg/m
2) 24.8+4.5
Primary infertility, n (%) 97 (64%)
Duration of infertility (years) 2.8+1.7
Previous cycles of ovulation induction (all) 4.9+2.4
Previous cycles of ovulation induction (with clomiphene
citrate)
4.1+2.4
Clomiphene citrate non-responders, n (%)
Failure to ovulate on clomiphene citrate
a 51 (34%)
Failure to conceive on clomiphene citrate
b 100 (66%)
Menstrual cycle history, n (%)
Amenorrhea 23 (15%)
Oligomenorrhea 84 (56%)
Anovulatory cycles with cycle length 21–35 days 44 (29%)
Sonographic parameters
Mean ovarian volume (cm
3) 7.1+3.5
Antral follicles .2 mm 14.8+12.5
Endometrial thickness (mm) 4.1+2.2
Endocrine parameters
LH (IU/l) 7.1+4.6
FSH (IU/l) 5.5+2.4
LH/FSH ratio 1.4+0.8
Prolactin (mg/l) 16+13
Androstenedione (nmol/l) 6.74+3.08
Total testosterone (nmol/L) 1.8+0.6
Sex hormone binding globulin (nmol/l) 61+40
Free androgen index 4.45+3.47
Estradiol (pmol/l) 172+98
Glucose (mmol/l)
Fasting 5.1+0.6
Non-fasting 5.2+1.5
Insulin (pmol/l)
Fasting 66.4+43.1
Non-fasting 143.9+192.6
All data are mean+SD or number of patients (percentage of patients).
aOn at least 5 days of 100 mg/day.
bAfter three cycles.
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CI: 0.97–6.79] for amenorrhea and oligomenorrhea, respect-
ively, compared with anovulatory cycles with a length of
21–35 days. The observed data for these three independent
predictors are presented in Table III.
The model predicted the FSH threshold dose to be the same
as the dose observed in the study for 59% of the patients. The
AUC under the ROC curve was 0.78 for 75 IU (Fig. 1a) and
0.79 for 112.5 IU (Fig. 1b). In a multiple regression analysis
with the same three variables as in the logistic model, the
FSH threshold dose was estimated on a continuous scale.
From this estimation, the residual mean square error was
25 IU and the R
2 ¼ 25%.
A simple nomogram can be constructed based on the two
clinical and one sonographic parameters that signiﬁcantly
predict the FSH threshold dose. Figure 2 displays three nomo-
grams—one for each type of menstrual cycle history—where
the shaded areas indicate the predicted FSH threshold dose,
based on the BMI displayed on the x-axis and mean ovarian
volume on the y-axis. For example, the expected threshold
FSH dose for a patient with amenorrhea (Fig. 2a), mean
ovarian volume of 10.5 cm
3 and a BMI of 30 kg/m
2 will be
150 IU. In the case that the patient presents with oligomenor-
rhea (Fig. 2b), but similar mean ovarian volume and BMI,
the expected threshold FSH dose would be 112.5 IU. As
another example, a threshold FSH dose of 75 IU will be
expected for a patient with anovulatory cycles of 21–35
days, mean ovarian volume of 8.5 cm
3 and BMI 27 kg/m
2,
whereas it will be 112.5 IU for a patient with oligomenorrhea
and similar mean ovarian volume and BMI.
The accuracy of the model was 60% when applied to the
subset of patients with mono-follicular development (80
patients), and thus similar to that achieved for the overall
study population.
Discussion
The main ﬁnding in the present study was identiﬁcation of the
three variables: menstrual cycle history, BMI and mean ovarian
volume, as independent predictors of the FSH threshold dose
during FSH treatment of anovulatory infertility. For clinical
use, such data could be implemented and used as screening pre-
dictors to determine the individual FSH threshold dose of any
patient before start of gonadotrophin treatment, in order to
select the most appropriate starting dose. For this purpose,
we have used the three independent predictors to develop the
FSH dose nomograms presented in Fig. 2. The proposed
model had an accuracy of 59–60%, which is well above the
25% that would be expected by random allocation to one of
the four dose levels evaluated in this study.
Our ﬁndings are partly in line with those obtained by Imani
et al. (2002) who studied 90 anovulatory women, also treated
with either urinary or rFSH, and showed that BMI, clomiphene
resistance, free IGF-1 and basal FSH were independent predic-
tors of the FSH threshold dose. Imani et al. (2002) made an
equation showing that the predicted dose was: [4 BMI (in
kg/m
2)] þ [32 clomiphene citrate resistance (yes ¼ 1o r
no ¼ 0] þ [7 initial free IGF-I (in ng/ml)] þ [6 initial serum
FSH level (in IU/l)] 2 51. Similar to our study, it was found
that menstrual bleeding interval as well as clomiphene
Table II. Statistically signiﬁcant predictors of FSH threshold dose (univariate and multivariate analysis).
Univariate analysis Multivariate analysis
OR (95% CI) P-value
a OR (95% CI) P-value
a
Age (years) 0.91 (0.83–1.00) 0.040 — —
BMI (kg/m
2) 1.10 (1.02–1.19) 0.010 1.17 (1.07–1.29) ,0.001
Failure to ovulate on clomiphene citrate: yes versus no 2.27 (1.14–4.52) 0.020 — —
Menstrual cycle history ,0.001 ,0.001
Amenorrhea versus cycle length 21–35 days 8.33 (2.81–24.7) 11.88 (3.35–42.1)
Oligomenorrhea versus cycle length 21–35 days 3.48 (1.51–8.03) 2.57 (0.97–6.79)
Mean ovarian volume (cm
3) 1.18 (1.06–1.31) 0.002 1.22 (1.08–1.37) ,0.001
Free androgen index (nmol/l) 1.25 (1.13–1.38) ,0.001 — —
Total testosterone (nmol/l) 2.14 (1.14–4.03) 0.018 — —
LH/FSH ratio (IU/l) 1.59 (1.03–2.45) 0.038 — —
aWald test for effect of factor/covariate.
Table III. BMI, mean ovarian volume and menstrual cycle history by observed FSH threshold dose.
BMI (kg/m
2) Mean ovarian volume (cm
3) Menstrual cycle history (%)
Amenorrhea / oligomenorrhea /
cycle length 21–35 days
75 IU (n ¼ 67) 23.8+4.2 6.3+2.9 8% / 48% / 45%
112.5 IU (n ¼ 46) 25.5+4.8 7.3+3.4 22% / 63% / 15%
150 IU (n ¼ 15) 25.8+4.0 9.5+4.8 33% / 47% / 20%
187.5 IU (n ¼ 4) 28.1+4.6 10.2+2.3 25% / 75% / 0%
All data are mean+SD or percentage of patients.
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but among the possible clinical predictors only clomiphene
resistance and BMI remained signiﬁcant in the multivariable
analysis. The population studied by Imani et al. (2002) seems
very similar to the present study, even though the latter
included patients if they failed to conceive after three clomi-
phene cycles, whereas the study by Imany et al. (2002) only
included women with six failed ovulatory clomiphene citrate
cycles, but it seems unlikely that this would explain the differ-
ence in predictive factors. A more plausible explanation could
be that the study by Imani et al. (2002) included, in the forward
step-wise multivariate analysis, some endocrine factors, such
as free-IGF-I and its binding proteins, that may alter the predic-
tors that remained in the ﬁnal model during the analysis.
It is worth brieﬂy discussing a statistical methodological
difference between the present model and that suggested by
Imani et al. (2002). The polytomous logistic regression model
used on the present data set predicts FSH threshold doses that
correspond to actual dose levels applied in the clinical trial, in
contrast to a multiple regression where the predicted dose is
on the continuous scale, as the equation published by Imani
et al. (2002). In our model, the residual mean square error was
25 IU and therefore the individual prediction is at least as
good as in the model suggested by Imani et al.( 2 0 0 2 )w h e r e
the residual mean square error was 35 IU. The R
2 value of
25% in the present model is explained by the relatively few
patients in the two highest dose levels in our trial compared
with a more even distribution of patients in the trial conducted
by Imani et al. (2002) yielding an R
2 of 39% in their model.
Our ﬁnding that the menstrual status was important is in line
with expectations. Patients with amenorrhea may need more
FSH to reach the threshold than a patient with oligomenorrhea,
who may also need more FSH compared with patients with
anovulatory cycles, indicating that the severity of the ovarian
dysfunction may well be reﬂected in the degree of menstrual
cycle disturbance. The relative resistance toFSH in amenorrheic
patients is supported by the ﬁnding that these patients also
have a relative resistance to endogenously released FSH
during clomiphene citrate treatment (Imani et al., 1998), as
patients with clomiphene resistance do release a similar
amount of endogenous FSH as the clomiphene sensitive
women (Polson et al., 1989). This supports the concept that it
is indeed the threshold of the ovarian sensitivity that is altered.
A high BMI was associated with a higher FSH threshold
dose; an observation that is supported by the ﬁndings that the
total dose of gonadotrophins needed to induce ovulation is
increased in parallel with body weight (Hamilton-Fairly
et al., 1992; Balen et al., 2006). The cause of the association
with BMI may be that the endocrine disturbance is related to
the degree of body fat and hyperinsulinaemia, but it may also
be due to a lower bioavailability of exogenous gonadotrophins
in obese women (Chan et al., 2003; Steinkampf et al., 2003).
The type of gonadotrophin used for stimulation was not a
signiﬁcant predictor of FSH threshold dose, and thus of
limited relevance compared with the patient’s clinical
characteristics.
In theory, the threshold is deﬁned as the lowest dose that
induces growth of the single most sensitive follicle. In this
clinical trial, a dual criterion for hCG administration was
used, covering not only the development of a single dominant
follicle, deﬁned as one follicle of 17 mm or greater, but also the
presence of 2–3 follicles of 15 mm or greater. Therefore, our
threshold is based on the stimulation in those 132 (87%)
patients who reached either of these criteria, including those
patients with up to 3 follicles  15 mm. The threshold dose
in the study and subsequently the model could also be termed
the ‘response dose’ and can be viewed as a surrogate for the
real threshold. It should be considered that serum FSH may
accumulate over time so the theoretically ideal threshold
should be deﬁned as the dose that caused growth of a single
dominant follicle to around 9–10 mm, where dominance is
normally established. The exact timing of dominance was not
determined in the present study, but it is important to note
that the model for threshold dose predictions also applied in
the subset of patients with mono-follicular development
deﬁned as only one follicle  17 and no follicles of 15–
16 mm. The average number of follicles  15 mm was 1.5
(Balen et al., 2007) indicating that some patients did indeed
receive FSH doses slightly above the threshold for single domi-
nant follicle development. However, the analysis restricted to
patients with mono-follicular development showed that the
accuracy of the model was the same for this subset of patients
Figure 1: ROCcurvesforthresholddose(a)75IUversus,75(AUC ¼
0.78) and (b)  112.5 IU versus .112.5 IU (AUC ¼ 0.79).
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to treat population in the present study, 92% of the patients
received hCG and the ongoing pregnancy rate was 19%, of
which 79% accounted for singletons and 21% for multiple
pregnancies (Balen et al., 2007). These ﬁgures are much in
line with literature data on 7 day step-up protocols (Homburg
and Howles, 1999), but it could be argued that the multiple
pregnancy rate is somewhat high, compared with a number
of recent studies using starting doses of FSH ,75 IU/day
(Balasch et al., 2000; Calaf Alsina et al., 2003). Indeed,
multiple pregnancy rates as low as 6% have been reported in
a large clinical trial using starting doses of 50 IU/day, even
though up to 3 follicles .16 mm before hCG administration
was accepted (Calaf Alsina et al., 2003). An alternative
approach is to restrict hCG administration to those patients
who have only one or two mature follicles, but this would
increase the cancellation rates. As published (Balen et al.,
2007), 3.3% (5/151) of the patients had their cycle cancelled
before hCG, due to development of multiple follicles. Identiﬁ-
cation of these patients with a very low threshold would have
necessitated a starting dose of ,75 IU/l.
Ovarian volume was another signiﬁcant parameter predict-
ing the FSH threshold dose. The larger the ovaries, the more
FSH was needed to obtain adequate ovarian response. This
ﬁnding is consistent with earlier clinical studies of ovulation
induction with gonadotrophins, where it has been shown that
patients with larger ovaries need longer duration of stimulation
and higher doses of gonadotrophins (Lass et al., 2002).
Van den Meer et al. (1994) studied three consecutive cycles
in 16 patients during gradually increased doses of intrave-
nously infused urinary FSH and elegantly documented how
the inter-individual variability in FSH threshold dose was far
greater than the variability from cycle to cycle. The key
problem is therefore to deﬁne the appropriate dose for any indi-
vidual patient and the present study provides a suggestion for
nomograms that may be used clinically. A major concern, if
patients were dosed according to the nomograms, would be
that 13% would receive a higher starting dose that the observed
threshold dose. The implications of an excessive starting dose
are likely to be the same as when step-down protocols are used,
i.e. risk of multiple follicular development. Indeed, van Sant-
brink et al. (2002) have used the prediction model developed
by the same group of investigators (Imani et al., 2002), and ret-
rospectively evaluated the doses used in a step-down regimen.
In that study, even though the average excessive dose was
28.5 IU/day above the threshold, the step-down approach
resulted in an overall multiple pregnancy rate of 17% and not
a single case of OHSS (van Santbrink et al., 2002).
The expected main advantage of dosing according to the
nomogram would be a shortening of the stimulation phase. It
is important to note that the suggested dosage nomograms
could be easily used clinically because they only include
simple characteristics that are routinely recorded in all anovu-
latory patients. Before using this model in clinical practice, a
randomized controlled trial should be conducted to compare
the presently used low-dose step-up protocol with a ﬂexible
protocol using this model.
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